Systemic Therapy for Hereditary Breast Cancers

Treatment options for patients with hereditary breast cancers have expanded significantly in the past 20 years. These include a new FDA-licensed approach to adjuvant therapy, olaparib, that improves OS in those with gBRCA1/2m. However, resistance to platinum-based chemotherapy and PARPi in this cohort of patients is an issue that requires considerable focus. We have discussed standard approaches to treatment, but have touched on the expanse of pre-clinical and early clinical work being undertaken which will likely shape future treatments in this field of medicine.

Automated summary

Treatment options for hereditary breast cancer patients have greatly expanded in the past 20 years, including the FDA-licensed olaparib which improves overall survival in patients with gBRCA1/2 mutations. However, resistance to platinum-based chemotherapy and PARPi is a significant issue for these patients.